Millennium Management
TLX

Millennium Management’s Telix Pharmaceuticals TLX Stock Holding History

Millennium Management’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,733
Closed -$148K – 6532
2025
Q4 		$148K Sell
19,733
-177,008
-90% -$1.7M ﹤0.01% 5550
2025
Q3 		$1.88M Buy
+196,741
New +$2.41M ﹤0.01% 4110

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $6.97B AUM 29.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Millennium Management's TLX Position: Q1 2026 in Review

Millennium Management sold out of Telix Pharmaceuticals (TLX) in Q1 2026, closing a stake of 19,733 shares — an estimated $148K sold.

Millennium Management first reported a position in TLX in Q3 2025 and held it in 2 quarters. The position peaked at $1.88M in Q3 2025. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • Millennium Management reported no remaining Telix Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 19,733 Telix Pharmaceuticals shares in Q1 2026, an estimated $148K.
  • Millennium Management first reported a position in Telix Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Millennium Management's Telix Pharmaceuticals position peaked at $1.88M in Q3 2025.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.